RS51263B - Hemijski proces - Google Patents
Hemijski procesInfo
- Publication number
- RS51263B RS51263B RSP-2010/0037A RSP20100037A RS51263B RS 51263 B RS51263 B RS 51263B RS P20100037 A RSP20100037 A RS P20100037A RS 51263 B RS51263 B RS 51263B
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- formula
- solvent
- mixture
- base
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Proces za proizvodnju jedinjenja sa Formulom VI:gde R1 je zaštitna grupa labilne kiseline iz jedinjenja sa Formulom VII:naznačen time, da pomenuti proces obuhvata:(g) reakciju jedinjenja sa Formulom VII sa prikladnim agensom za hlorovanje u prisutnosti prikladne baze i prikladnog rastvarača, gde je reakcija provodi uz pomoć:(g-1) dodavanja mešavine jedinjenja sa Formulom VII i baze u rastvaraču u mešavinu agensa za hlorovanje u rastvaraču na temperaturi u rasponu od 60 do 90° C tokom perioda od oko 60 min; ili (g-2) dodavanja agensa za hlorovanje u mešavinu jedinjenja sa Formulom VII i baze u rastvaraču na ambijentalnoj temperaturi tokom perioda od oko 15 min, a tada uz pomoć grejanja reakcione mešavine tokom perioda od oko 90 min na temperaturi u rasponu od 70 do 90° C i uz mešanje reakcione mešavine na istoj temperaturi od oko 1 h; ili (g-3) dodavanja agensa za hlorovanje u mešavinu jedinjenja sa Formulom VII i baze u rastvaraču na temperaturi u rasponu od 60 do 110° C tokom perioda od oko 15 min, a sa ciljem dobijanja jedinjenja sa Formulom VIII:(h) reakciju jedinjenja sa Formulom VIII sa 4-bromo-2-fluoroanilinom in situ u prisutnosti rastvarača koji se koristi u koraku (g) sa ciljem nastajanja hlorovodonične soli jedinjenja sa Formulom VI;i gde jedinjenje sa Formulom VI, dobiveno u formi hlorovodonične soli, može da se konvertuje u slobodnu bazu ili u formu neke alternativne soli, ako je potrebno.Prijava sadrži još 27 patentnih zahteva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519879.1A GB0519879D0 (en) | 2005-09-30 | 2005-09-30 | Chemical process |
| PCT/GB2006/003587 WO2007036713A2 (en) | 2005-09-30 | 2006-09-27 | Chemical process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS51263B true RS51263B (sr) | 2010-12-31 |
Family
ID=35395001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2010/0520A RS51515B (sr) | 2005-09-30 | 2006-09-27 | Hemijski in situ postupak sulfoniranja |
| RSP-2010/0037A RS51263B (sr) | 2005-09-30 | 2006-09-27 | Hemijski proces |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2010/0520A RS51515B (sr) | 2005-09-30 | 2006-09-27 | Hemijski in situ postupak sulfoniranja |
Country Status (32)
| Country | Link |
|---|---|
| US (8) | US8163926B2 (sr) |
| EP (2) | EP1943240B1 (sr) |
| JP (2) | JP5213715B2 (sr) |
| KR (1) | KR101307641B1 (sr) |
| CN (3) | CN102503933B (sr) |
| AR (1) | AR055671A1 (sr) |
| AT (2) | ATE481399T1 (sr) |
| AU (1) | AU2006296367B2 (sr) |
| BR (1) | BRPI0616715A2 (sr) |
| CA (2) | CA2624045C (sr) |
| CY (2) | CY1110275T1 (sr) |
| DE (2) | DE602006010428D1 (sr) |
| DK (2) | DK2053048T3 (sr) |
| ES (2) | ES2335435T3 (sr) |
| GB (1) | GB0519879D0 (sr) |
| HK (2) | HK1122553A1 (sr) |
| HR (2) | HRP20100019T1 (sr) |
| IL (2) | IL190172A (sr) |
| ME (2) | ME01466B (sr) |
| MY (2) | MY145540A (sr) |
| NO (1) | NO342152B1 (sr) |
| NZ (2) | NZ566566A (sr) |
| PL (2) | PL1943240T3 (sr) |
| PT (2) | PT2053048E (sr) |
| RS (2) | RS51515B (sr) |
| RU (1) | RU2448102C2 (sr) |
| SG (1) | SG165416A1 (sr) |
| SI (2) | SI2053048T1 (sr) |
| TW (2) | TWI424991B (sr) |
| UY (1) | UY29824A1 (sr) |
| WO (1) | WO2007036713A2 (sr) |
| ZA (1) | ZA200802416B (sr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81619C2 (ru) * | 2002-02-01 | 2008-01-25 | Астразенека Аб | Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе |
| GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
| US7851623B2 (en) * | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
| EP2404595B1 (de) * | 2011-09-01 | 2015-08-05 | Symrise AG | Verfahren zur Herstellung von Indanon-Derivaten |
| CN107163038B (zh) * | 2012-08-15 | 2020-07-28 | 葛兰素集团有限公司 | 化学方法 |
| CN104098544A (zh) * | 2013-04-07 | 2014-10-15 | 浙江九洲药物科技有限公司 | 一种凡德他尼的制备方法 |
| CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870083A (en) * | 1987-11-24 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants |
| JP2829744B2 (ja) | 1989-05-31 | 1998-12-02 | 川研ファインケミカル株式会社 | ピペリジンカルボン酸類の製造方法 |
| AU8506791A (en) | 1990-10-01 | 1992-04-28 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
| ES2188584T3 (es) | 1991-03-28 | 2003-07-01 | Eisai Co Ltd | Derivados heterociclicos de amina. |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2118117A1 (en) | 1993-02-18 | 1994-08-19 | Shigeki Fujiwara | Adenosine uptake inhibitor |
| NZ267296A (en) | 1993-05-26 | 1997-04-24 | Syntex Inc | 4-(aminophenyl) omega amino- or 4-piperidyl- alkyl ketone derivatives; pharmaceutical compositions |
| DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CA2180746A1 (en) * | 1994-01-13 | 1995-07-20 | Raymond Baker | Gem-disubstituted azacyclic tachykinin antagonists |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| EP0885198B1 (en) | 1996-03-05 | 2001-12-19 | AstraZeneca AB | 4-anilinoquinazoline derivatives |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ES2306306T3 (es) * | 1999-11-05 | 2008-11-01 | Astrazeneca Ab | Nuevos derivados de quinazolina. |
| GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| AU2002366801B8 (en) | 2001-12-20 | 2009-05-21 | Osi Pharmaceuticals, Inc. | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| UA81619C2 (ru) | 2002-02-01 | 2008-01-25 | Астразенека Аб | Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе |
| AU2003207291A1 (en) | 2002-02-06 | 2003-09-02 | Ube Industries, Ltd. | Process for producing 4-aminoquinazoline compound |
| WO2004014383A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| CA2514227C (en) | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
| KR20120093411A (ko) | 2003-07-10 | 2012-08-22 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도 |
| GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
-
2005
- 2005-09-30 GB GBGB0519879.1A patent/GB0519879D0/en not_active Ceased
-
2006
- 2006-09-27 NZ NZ566566A patent/NZ566566A/en not_active IP Right Cessation
- 2006-09-27 CN CN201110159628.2A patent/CN102503933B/zh active Active
- 2006-09-27 ES ES06794582T patent/ES2335435T3/es active Active
- 2006-09-27 EP EP06794582A patent/EP1943240B1/en active Active
- 2006-09-27 KR KR1020087009317A patent/KR101307641B1/ko active IP Right Grant
- 2006-09-27 PT PT09152654T patent/PT2053048E/pt unknown
- 2006-09-27 ME MEP-2013-21A patent/ME01466B/me unknown
- 2006-09-27 PL PL06794582T patent/PL1943240T3/pl unknown
- 2006-09-27 BR BRPI0616715-2A patent/BRPI0616715A2/pt not_active IP Right Cessation
- 2006-09-27 DE DE602006010428T patent/DE602006010428D1/de active Active
- 2006-09-27 AT AT09152654T patent/ATE481399T1/de active
- 2006-09-27 AU AU2006296367A patent/AU2006296367B2/en not_active Ceased
- 2006-09-27 JP JP2008532864A patent/JP5213715B2/ja not_active Expired - Fee Related
- 2006-09-27 ES ES09152654T patent/ES2350513T3/es active Active
- 2006-09-27 EP EP09152654A patent/EP2053048B8/en active Active
- 2006-09-27 DE DE602006017004T patent/DE602006017004D1/de active Active
- 2006-09-27 CN CN201110159729.XA patent/CN102503898B/zh active Active
- 2006-09-27 ME MEP-2013-51A patent/ME01531B/me unknown
- 2006-09-27 SG SG201006940-9A patent/SG165416A1/en unknown
- 2006-09-27 DK DK09152654.1T patent/DK2053048T3/da active
- 2006-09-27 CA CA2624045A patent/CA2624045C/en not_active Expired - Fee Related
- 2006-09-27 MY MYPI20080855A patent/MY145540A/en unknown
- 2006-09-27 WO PCT/GB2006/003587 patent/WO2007036713A2/en active Application Filing
- 2006-09-27 MY MYPI2011003076A patent/MY149834A/en unknown
- 2006-09-27 SI SI200630816T patent/SI2053048T1/sl unknown
- 2006-09-27 CN CN200680036468XA patent/CN101277948B/zh active Active
- 2006-09-27 DK DK06794582.4T patent/DK1943240T3/da active
- 2006-09-27 PT PT06794582T patent/PT1943240E/pt unknown
- 2006-09-27 CA CA2745829A patent/CA2745829C/en not_active Expired - Fee Related
- 2006-09-27 US US12/088,680 patent/US8163926B2/en active Active
- 2006-09-27 SI SI200630524T patent/SI1943240T1/sl unknown
- 2006-09-27 PL PL09152654T patent/PL2053048T3/pl unknown
- 2006-09-27 RS RSP-2010/0520A patent/RS51515B/sr unknown
- 2006-09-27 RS RSP-2010/0037A patent/RS51263B/sr unknown
- 2006-09-27 RU RU2008116573/04A patent/RU2448102C2/ru not_active IP Right Cessation
- 2006-09-27 NZ NZ593930A patent/NZ593930A/xx not_active IP Right Cessation
- 2006-09-27 AT AT06794582T patent/ATE448218T1/de active
- 2006-09-29 AR ARP060104320A patent/AR055671A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29824A patent/UY29824A1/es unknown
- 2006-09-29 TW TW099102690A patent/TWI424991B/zh not_active IP Right Cessation
- 2006-09-29 TW TW095136340A patent/TWI328580B/zh not_active IP Right Cessation
-
2008
- 2008-03-11 NO NO20081267A patent/NO342152B1/no not_active IP Right Cessation
- 2008-03-13 IL IL190172A patent/IL190172A/en not_active IP Right Cessation
- 2008-03-14 ZA ZA200802416A patent/ZA200802416B/xx unknown
- 2008-12-15 HK HK08113582.9A patent/HK1122553A1/xx not_active IP Right Cessation
-
2009
- 2009-09-21 HK HK09108619.5A patent/HK1130478A1/xx not_active IP Right Cessation
-
2010
- 2010-01-11 HR HR20100019T patent/HRP20100019T1/hr unknown
- 2010-01-25 CY CY20101100076T patent/CY1110275T1/el unknown
- 2010-11-12 CY CY20101101019T patent/CY1110887T1/el unknown
- 2010-11-16 HR HR20100620T patent/HRP20100620T1/hr unknown
-
2011
- 2011-12-07 US US13/314,034 patent/US8865899B2/en active Active
-
2012
- 2012-11-28 JP JP2012259782A patent/JP5654546B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-21 IL IL227574A patent/IL227574A/en not_active IP Right Cessation
-
2014
- 2014-09-09 US US14/481,302 patent/US20140378684A1/en not_active Abandoned
-
2015
- 2015-07-22 US US14/805,816 patent/US9815816B2/en active Active
-
2017
- 2017-10-27 US US15/796,615 patent/US10344015B2/en active Active
-
2019
- 2019-05-08 US US16/406,246 patent/US20190263782A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/086,666 patent/US20220033377A1/en not_active Abandoned
-
2023
- 2023-03-07 US US18/118,549 patent/US20240150317A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS51263B (sr) | Hemijski proces | |
| Huh et al. | An efficient method for one-carbon elongation of aryl aldehydes via their dibromoalkene derivatives | |
| WO2004074502A3 (en) | A process of preparing imatinib | |
| HRP20040690B1 (en) | Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals | |
| EP1724248A4 (en) | PROCESS FOR PRODUCING AROMATIC COMPOUNDS | |
| Zhang et al. | Base-controlled three component reactions of amines, elemental sulfur, and styrenes: synthesis of thioamides under metal-free conditions | |
| ATE413377T1 (de) | Verfahren zur kontinuierlichen quaternisierung tertiärer amine mit einem alkylhalogenid | |
| Wright et al. | Bench-Stable Transfer Reagent Facilitates the Generation of Trifluoromethyl-sulfonimidamides | |
| Tada et al. | Smiles-type free radical rearrangement of aromatic sulfonates and sulfonamides: syntheses of arylethanols and arylethylamines | |
| Chen et al. | Visible-light-driven intramolecular xanthylation of remote unactivated C (sp3)-H bonds | |
| HRPK20040287B3 (en) | Process for the preparation of citalopram | |
| CN112661584B (zh) | 一种光催化n-烷基酰胺化合物的制备方法 | |
| Zheng et al. | Copper-catalyzed three-component redox-neutral ring opening of benzothiazoles to 1-amino-N-(2-(phenylthio) phenyl) methanimine | |
| SE0401001D0 (sv) | Chemical process | |
| CN104151220A (zh) | N，n’-二烷基二硫代草酰胺及其制备方法和用途 | |
| Liu et al. | A facile solid phase synthesis of tetramic acid | |
| US20230382887A1 (en) | Process for the preparation of chlorantraniliprole | |
| Yagupolskii et al. | Perfluoroalkylation of heterocumulenes with trimethyl (perfluoroalkyl) silanes in the presence of fluoride ions: synthesis of perfluoroalkanesulfinyl amides from N-organylsulfinyl amines | |
| CN109438299B (zh) | 一种苯磺酰肼类衍生物与三乙胺无金属催化合成苯磺酰烯胺类化合物的方法 | |
| CN103351340B (zh) | 唑虫酰胺的新制备方法 | |
| TW201825474A (zh) | 製備殺蟲劑化合物的方法 | |
| CA2556766A1 (en) | Synthesis of sterically hindered secondary aminoether alcohols | |
| CA2556508A1 (en) | Synthesis of sterically hindered secondary aminoether alcohols | |
| CA2555530A1 (en) | Synthesis of sterically hindered secondary aminoether alcohols from acid anhydride and/or acid halide and sulfur trioxide | |
| CN109369506B (zh) | 一种选择性n-甲基化二级酰胺的方法 |